Astellas, Dell Of U.S. To Partner On Cancer-Drug Biomarkers
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and Dell Signaling Technology of the United States signed a partnership agreement to collaborate on research for biomarkers to serve as diagnostic reagents, beginning with those leading to cancer drugs